1. Principal Investigator - Xplore: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration.
  2. Principal Investigator - A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration.
  3. Principal Investigator - A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared with Latanoprost Ophthalmic Solution 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension.
  4. Principal Investigator - Bioequivalence study with clinical endpoint comparing brinzolamide 1% ophthalmic suspension of Watson pharma to Alcon laboratories in the treatment of chronic open angle glaucoma or ocular hypertension in both eyes.
  5. Principal Investigator - A Clinical Study to evaluate the Efficacy, Safety and Tolerability of Brinzolamide 1.0% w/v plus Brimonidine Tartrate 0.2 % w/v Ophthalmic Suspension Vs. Brinzolamide 1% eye drops in patients with Open-Angle Glaucoma or Ocular Hypertension
  6. Principal Investigator - Clinical evaluation of contact lens with hyper osmotic drops in corneal edema (Eye Yon Medical, Israel)
  7. Principal Investigator - An open label, multicentric, observational study to evaluate safety and efficacy of various tear substitutes in patients suffering from Dry eye disease